Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT(TM) in Malignant Skin and Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events
JERUSALEM, Jan. 10, 2022 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that all ten patients in its US multi-center ... Devices, Oncology Alpha Tau Medical, Alpha DaRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 10, 2022 Category: Pharmaceuticals Source Type: news
Telix, Olivia Newton-John Cancer Research Institute to collaborate
Telix Pharmaceuticals plans to collaborate with the Olivia Newton-John Cance...Read more on AuntMinnie.comRelated Reading:
Telix secures FDA clearance for prostate cancer PET imaging agent
Telix applauds NCCN radiotracer update
Telix, Kettering to research PSMA radiotracer
Lightpoint, Telix ink collaboration agreement
Telix works with Merck on cancer therapies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 4, 2022 Category: Radiology Source Type: news
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head and Neck Cancer
JERUSALEM, Jan. 3, 2022 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has been notified by HekaBio K.K., its... Devices, Oncology Alpha Tau Medical, Alpha DaRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 3, 2022 Category: Pharmaceuticals Source Type: news
Telix secures FDA clearance for prostate cancer PET imaging agent
Telix Pharmaceuticals has secured clearance from the U.S. Food and Drug Administratio...Read more on AuntMinnie.comRelated Reading:
Telix applauds NCCN radiotracer update
Telix, Kettering to research PSMA radiotracer
Lightpoint, Telix ink collaboration agreement
Telix works with Merck on cancer therapies
Telix Japan names COO (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 20, 2021 Category: Radiology Source Type: news
Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer Therapy Switch Based on Mutation May Prolong PFS in Breast Cancer
Patients with metastatic disease receiving aromatase inhibitor plus palbociclib and with a rising ESR1 mutation may benefit from early switch to fulvestrant plus palbociclib.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Immatics inks $920M licensing deal with Bristol Myers Squibb
Immatics, which develops a pipeline of cancer therapies, has an administrative office and a research laboratory in Houston. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 14, 2021 Category: Biotechnology Authors: Chris Mathews Source Type: news
Cellogen to bring next-gen cancer therapy to India
"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to offer IGIB's expertise in genome manipulation towards translational efforts in this area", said Dr. Anurag Agrawal, Director, CSIR-IGIB at the inking of the agreement with Cellogen Therapeutics. (Source: The Economic Times)
Source: The Economic Times - December 13, 2021 Category: Consumer Health News Source Type: news
No Benefit to Adding Palbociclib to Early Breast Cancer Therapy No Benefit to Adding Palbociclib to Early Breast Cancer Therapy
A phase 3 trial now confirms no benefit to adding palbociclib to endocrine therapy in early HR-positive, HER2-negative breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 10, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New tracer bests FDG for diagnosing liver cancer
PET/CT imaging of hepatocellular carcinoma with an experimental gallium-68-base...Read more on AuntMinnie.comRelated Reading:
Sofie receives nod to start trial for PET tracer
PET imaging lays foundation for new cancer therapies
PET tracer shows promise for diagnosing breast cancer
Sofie submits IND application for pancreatic PET agent
New PET radiotracer more effective at detecting cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 10, 2021 Category: Radiology Source Type: news
Advancements Series to Explore Breakthroughs in Biopharmaceutical...
Get an inside look at the next generation of medicines for cancer therapy.(PRWeb December 09, 2021)Read the full story at https://www.prweb.com/releases/advancements_series_to_explore_breakthroughs_in_biopharmaceutical_technology/prweb18382243.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2021 Category: Pharmaceuticals Source Type: news
Antimicrobial Resistance Calls for Brainpower of a Space Agency and Campaigning Zeal of an NGO
This article is republished from The Conversation under a Creative Commons license. Read the original article. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - November 17, 2021 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health Source Type: news
Actym Therapeutics Appoints Chan Whiting as Chief Development Officer
BERKELEY, Calif., Nov. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the ... Biopharmaceuticals, Oncology, Personnel Actym Therapeutics, S. Typhimurium-Attenuated Cancer Therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 11, 2021 Category: Pharmaceuticals Source Type: news
PET imaging lays foundation for new cancer therapies
PET imaging of cancer patients with an experimental gallium-68 (Ga-68) trace...Read more on AuntMinnie.comRelated Reading:
PET tracer shows promise for diagnosing breast cancer
Sofie submits IND application for pancreatic PET agent
New PET radiotracer more effective at detecting cancer
PET detects activity in early atherosclerosis
Animal study suggests Ga-68 PET FAPI can detect lung fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 8, 2021 Category: Radiology Source Type: news
Changing Cancer Care, So Patients No Longer Feel Like a Number
“Having cancer is terrifying. It’s scary. And going to the hospital—I really felt like a number,” says Marc Hulett, who was diagnosed with prostate cancer in 2004.
Hulett had surgery to remove his prostate and has been on hormone therapy for 17 years. Every three months, he gets a blood test to monitor his progress, but he no longer feels like a number. He drives from his home in Palm Springs, Calif., to Los Angeles—which can take up to six hours—to see his oncologist, Dr. David Agus, at the Ellison Institute for Transformative Medicine.
As the name suggests, the Institute isn’t ju...
Source: TIME: Health - November 3, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthscienceclimate Source Type: news
Inovio, AstraZeneca terminate cancer vaccine partnership
MedImmune Ltd., the global biologics research and development arm of AstraZeneca (NYSE: AZN), is terminating a cancer therapy partnership it has with Inovio Pharmaceuticals.
The partnership, formed in 2015, gave MedImmune of Gaithersburg, Maryland, exclusive rights to Inovio's experimental DNA-based cancer vaccine, known as INO-3112, for cancers caused by human papillomavirus (HPV) types 16 and 18.
MedImmune renamed the new drug candidate as MED10457 after acquirin g its exclusive rights. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2021 Category: Pharmaceuticals Authors: John George Source Type: news
